Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c...
Nasdaq News: Markets·13h ago